anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled composition containing copper gluconate and a polar solvent extract of plant of Camellia family, capable of completely eliminating foul breath composed of amine smell and sulfur compound smell by the use of an extremely small amount of the composition nd usable without causing color staining. CONSTITUTION:The objective composition contains (A) an extract produced by extracting leaf of a plant of Camellia family with a polar solvent, preferably with a 20-80% aqueous solution of glycerol at 50-100 deg.C and (B) copper gluconate. The amounts of the components A and B having deodorizing titer of (n) are nX(4.5-5.5)pts.wt. and 1pt.wt., respectively. The deodorizing titer is defined by the volume (m1) of 500ppm aqueous solution of the extract necessary to essentially eliminate the smell of 1ml of 1,000ppm aqueous solution of trimethylamine. The composition is added to mouth wash, chewing gum, candy, dentifrice, etc., at ratios of 0.0005-0.5wt% component A (in terms of 1.0 deodorizing titer) and 0.0001-0.1wt% component B.
An antiviral protein having an amino acid sequence represented by sequence No. 8 of a Sequence Listing is disclosed. The protein is obtained such that cysteine residues in the basic protein (MAP) obtained from Mirabilis jalapa and having antiviral activity are substituted with serine residues. More specifically, a MAP gene in which codons encoding cysteines are substituted with codons encoding serines is prepared, and this gene is integrated in a MAP secretion vector. This vector is introduced into a host to express the gene, thereby obtaining the antiviral protein. This protein retains MAP advantages as a toxic protein and has higher protein synthesis inhibition activity than that of MAP, and almost equal to that of a lysine A chain.
Achieving urinary continence in patients with bladder extrophy epispadias complex remains a challenging urological goal. Children with bladder extrophy epispadias complex generally undergo many surgical procedures for the treatment of sphincteric incompetence, including bladder neck reconstruction, slings and bulking agent injection. The key point in most of these procedures is to enhance urethral resistance, leading to some degree of bladder outlet obstruction. However, the reported 7% to 85% continence rates in these patients may not exactly represent those children who achieve volitional voiding through the urethra, but may also include the ones with bladder augmentation and urinary diversion. Endoscopic injection of bulking agent has emerged as a therapeutic approach in the treatment of urinary incontinence (UI). this procedure seems to be economical, with shorter hospitalization and fewer major complications. On the other hand, degradation, migration, reabsorption, overbulking, bladder outlet obstruction and hypersensitivity are frequently reported complications of bulking agents.

The ideal substance for periurethral injection should be durable, non immunogenic, nonmigratory and efficacious. So, transurethral implantation of autologous myoblasts may represent an improved alternative to synthetic bulking agents, with the unique ability to compensate for the deficient muscle fibers in the urethral sphincter. Patients with incontinence usually have decreased resting tone and contractility of the rhabdosphincter. In patients with bladder extrophy epispadias complex the perineal structures are dislocated laterally, and the internal and external urethral sphincters are deficient. Muscle precursor cells constantly regenerate striated muscles, and include the quiescent satellite cells located beneath the basal lamina of skeletal myofibers, which are responsible for repair of the terminally differentiated striated muscle tissue. After injury or in response to intensive physical exercise satellite cells proliferate and differentiate into myoblasts, which ultimately fuse to form new myofibers capable of muscle contraction. Considering the limited capacity of the rhabdosphincter for regeneration, the idea of urethral sphincter repair in patients with bladder extrophy epispadias COMPLEX via transurethral injection of autologous myoblasts has been suggested. The technical availability of these cells, as well as immunological acceptance and survival, makes them appropriate for this purpose. Satellite cells are committed cell lineage with restricted plasticity and do not multiply beyond the required repair needs. This property confers an acceptable measure of safety for clinical applications. The first clinical study of cell therapy based treatment of sphincter insufficiency, using muscle derived stem cell transplantation was carried out in patients with stress incontinence revealed and confirmed the ability of cell therapy to improve the structure and contractile function of the sphincter.
Prospective mixed methods pilot study, using both qualitative and quantitative measures. This study will be conducted in two phases. In Phase 1 (Year 1), the investigators plan to use a modified Delphi procedure called the RAND/UCLA Appropriateness Method in which the investigators will form a multidisciplinary panel to develop a consensus of incorporating the TIC practices based on FOCUS into current best practices for childhood obesity prevention and treatment among low-income minorities to be facilitated by primary care providers. In Phase 2 (Year 2), the investigators will train and implement the Primary Care Provider-mediated FOCUS TIC-COM among providers for obese children and their caregivers / parents in the MLK OPC Family Medicine Clinic. During this phase, the investigators plan to examine the feasibility and acceptability of delivering the FOCUS TIC-COM in the primary care setting at MLKOPC through surveys and focus groups with both providers and the parents / caregivers of overweight / obese children. The investigators will also explore whether the FOCUS TIC-COM impact on childhood obesity (as perceived by child's parent / caregiver) and increase linkages to behavioral health care regarding trauma / toxic stress. At 3 month intervals, the investigators will train a subset of providers in the intervention and they will implement the intervention immediately after training.
The term "ketogenic diet" (KD) is used for a wide variety of diets with diverse indications ranging from obesity to neurological diseases, as if it was the same diet. This terminology is confusing for patients and the medical and scientific community. The term "ketogenic" diet implies a dietary regimen characterized by increased levels of circulating ketone bodies that should be measured in blood (beta-hydroxybutyrate), urine (acetoacetate) or breath (acetone) to verify the "ketogenic metabolic condition". Our viewpoint highlights that KDs used for epilepsy and obesity are not the same; the protocols aimed at weight loss characterized by low-fat, low-CHO and moderate/high protein content are not ketogenic by themselves but may become mildly ketogenic when high calorie restriction is applied. In contrast, there are standardized protocols for neurological diseases treatment for which ketosis has been established to be part of the mechanism of action. Therefore, in our opinion, the term ketogenic dietary therapy (KDT) should be reserved to the protocols considered for epilepsy and other neurological diseases, as suggested by the International Study Group in 2018. We propose to adjust the abbreviations in VLCHKD for Very Low CarboHydrate Ketogenic Diet and VLEKD for Very Low Energy Ketogenic Diet, to clarify the differences in dietary composition. We recommend that investigators describe the researchers describing efficacy or side effects of KDs, to clearly specify the dietary protocol used with its unique acronym and level of ketosis, when ketosis is considered as a component of the diet's mechanism of action.
All cases met the (brain death) BD clinical evaluation criteria, which were as follows: the cause of coma was known; exclusion of reversible coma; deep coma, Glasgow coma scale (GCS) = 2T; absence of five brain stem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex); and no spontaneous respiration. Furthermore, according to whether the apnea test (AT) data were missing (implemented or completed), the patients were divided into the BD1 group (no AT missing group) and BD2 group (AT missing group).
This is a randomized double-blind placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. 30 SCT recipients will take part in the study. Participants with be randomly assigned (1:1) to either baloxavir + oseltamivir or baloxavir-matched placebo +oseltamivir. Before randomization, patients will be stratified by hospitalization status and influenza type A (yes/no).

Patients in the baloxavir combination arm will receive weight-adjusted baloxavir (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline and at day 4 and day 7. They will also receive oseltamivir 75 mg twice daily for 10 days. Patients in the baloxavir-matched placebo + oseltamivir arm will receive baloxavir-matched placebo at baseline and at day 3 and day 7and oseltamivir 75 mg twice daily for 10 days.
Problems with attention and perception are core features of schizophrenia and are hypothesized to result from defects in the filtering or gating of sensory input. Examination of this requires neuroimaging techniques with high temporal resolution. High-density EEG and MEG in combination with structural magnetic resonance imaging (sMRI) are used to map sensory gating. In a number of recent studies patient treated with novel antipsychotics have been shown to have P50 gating ratios resembling those of normal controls rather than that of schizophrenia subjects treatment with conventional antipsychotics. To date, there is no literature on the effects of aripiprzole on sensory gating. Subjects who meet all inclusion criteria will receive a clinical interview, an MRI, MEG, and neuropsychological testing before starting treatment with aripiprazole and again 3 months later to determine if patients with schizophrenia who are treated with aripiprazole will demonstrate a sensory gating ratio similar to normal controls, indicating no deficit in sensory gating
Anti-CD3 mAbs are potent immunosuppressive agents used in clinical transplantation. However, the activation-related adverse side effects associated with these mAbs have prompted the development of less toxic Fc receptor non-binding anti-CD3 mAb therapies. At present, the functional and biochemical consequences of T cell exposure to Fc receptor non-binding anti-CD3 is unclear. In this study, the inventors have examined the early signaling events triggered by a Fc receptor non-binding anti-CD3 mAb. Like the mitogenic anti-CD3 mAb, Fc receptor non-binding anti-CD3 triggered changes in the TCR complex, including z chain tyrosine phosphorylation and ZAP-70 association. However, unlike the mitogenic anti-CD3 stimulation, Fc receptor non-binding anti-CD3 was ineffective at inducing the highly phosphorylated form of z (p23) and tyrosine phosphorylation of the associated ZAP-70 tyrosine kinase. This proximal signaling deficiency correlated with minimal PLCη-1 phosphorylation and failure to mobilize detectable Ca2+. Not only did biochemical signals delivered by Fc receptor non-binding anti-CD3 resemble altered peptide ligand signaling, but exposure of Th1 clones to Fc receptor non-binding anti-CD3 also resulted in functional anergy. Finally, a bispecific anti-CD3 x anti-CD4 F(ab)'¿2? reconstituted early signal transduction events and induced proliferation, suggesting that defective association of 1ck with the TCR complex may underlie the observed signaling differences between the mitogenic and Fc receptor non-binding anti-CD3.
investigators review the medical records of patients who underwent tonsillectomy with or without adenoidectomy in our facility. None of the included patients had any known coagulopathy. The surgery was performed by several different surgeons, either otolaryngology residents or specialists, and using either cold or bipolar dissection. The procedures were performed under general anesthesia with orotracheal intubation. Bipolar electrocoagulation was used for hemostasis, as well as in some cases vicryl sutures. All medical records were reviewed according to age, gender, indications for tonsillectomy (tonsil hypertrophy causing upper airway obstruction, snoring or sleep apnea, chronic tonsillitis, peritonsillar abscess or suspected malignancy of the tonsils), coagulation profile \[international normalized ratio (INR) and activated partial thromboplastin time values (aPTT)\], type of surgery (tonsillectomy alone or adenotonsillectomy), surgical technique (cold or bipolar dissection), hemostasis method (bipolar electrocoagulation alone or electrocoagulation and sutures) and post-operative hemorrhage and its characterization. In this report, investigators will evaluate patients and collection of data to make a new scoring system that assesses patients according to several preoperative and postoperative factors to know the possibility of patients developing Post tonsillectomy hemorrhage. Post tonsillectomy hemorrhage is divided into two groups according to its severity: minimal hemorrhage that stopped spontaneously/after noninvasive treatment, and hemorrhage requiring reoperation for hemostasis revision in the operating room under general anesthesia.

Postoperative hemorrhage was defined as any bleeding requiring in hospital observation or treatment (medical, compression, cauterization under general anesthesia). Patients who did not seek medical attention (e.g., patients with blood-tinged sputum or only minor bleeding) were not included in the group with post-operative hemorrhage
The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
The invention relates to an idebenone succinate monoester and a preparation method thereof. Idebenone is a novel specific medicine for resisting senile dementia and an improver for improving the brain function and metabolism and psychotic symptoms and has multiple pharmacological effects. The idebenone has disadvantages of not being soluble in water and being only administrated orally. The idebenone succinate monoester disclosed by the invention has a structural formula shown in the specification, is soluble in both organic solvents and water and has better stability in water. When the idebenone succinate monoester is converted into corresponding water-soluble salts, the solubility of the idebenone succinate monoester in water can be improved further. The preparation method comprises the following steps of: dissolving idebenone and succinic anhydride (butanedioic anhydride) in an organic solvent, reacting at 0-100 DEG C under the catalysis of an alkaline substance for 1-1000h, removing the alkaline substance used as a catalyst with acid or acid salt to finally obtain the high-purity idebenone succinate monoester which is suitable for large-scale production. The compound and the corresponding water-soluble salts thereof can be prepared into both oral preparations and injections, and therefore, the application range of idebenone is greatly expanded.
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is an isolated antibody or antigen-binding fragment thereof for delivering a cytotoxin comprising a CH1 IgG domain, where the CH1 IgG domain contains an asparagine residue in the amino acid position 114 in accordance with the Kabat numbering, where the side chain of the said asparagine residue is linked to the glycan. Also described is an isolated antibody or its antigen-binding fragment for the delivery of a detection agent containing a CH1 IgG domain, where the CH1 domain of the IgG contains an asparagine residue in the amino acid position 114 in accordance with the Kabat numbering, where the side chain of the said asparagine residue is linked to the glycan. Also described is an isolated antibody or its antigen-binding fragment for the delivery of a cytotoxin containing a CH1 domain of IgG, where the CH1 domain of the IgG contains an asparagine residue in the amino acid position 114 in accordance with the Kabat numbering, where the side chain of said asparagine residue is bound to glycan by β-glycosylamide linkage and where glycan is linked to detection agent. Also described is an isolated antibody or antigen-binding fragment thereof for the delivery of a detection agent containing a CH1 IgG domain, where the CH1 IgG domain contains the asparagine residue in the amino acid position 114 in accordance with the Kabat numbering, where the side chain of said asparagine residue is bound to glycan by β-glycosylamide linkage and where glycan is linked to cytotoxin. Also disclosed is an isolated antibody or an antigen-binding fragment thereof for cytotoxin binding, containing an CH1 domain of IgG, wherein the CH1 domain of IgG contains a free asparagine residue in the position of amino acid 114 in accordance with the Kabat numbering. Disclosed is an isolated antibody or antigen-binding fragment thereof for binding a detection agent containing a CH1 IgG domain, wherein the CH1 domain of the IgG contains a free asparagine residue at amino acid position 114 in accordance with the Kabat numbering.EFFECT: invention can be used for treating cancer, for diagnostic use.36 cl, 35 dwg, 15 tbl, 15 ex
Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
PROBLEM TO BE SOLVED: To obtain a liquid pharmaceutical preparation of an antithrombin-III, stable in long-term preservation, hardly causing a reduction in blood pressure or cardiopathy even when administered and simply administrable. SOLUTION: This liquid pharmaceutical preparation of an antithrombin-III (hereinafter abbreviated to AT-III) comprises 10-500 units/ml, preferably 25-100 units/ml AT-III and 0.5-3wt./vol.%, preferably 1-1.5wt./vol.% gluconic acid or its salt therein. The liquid pharmaceutical preparation is obtained by further suitably blending a sugar (e.g saccharose) and a surfactant or an organic acid other than the gluconic acid (e.g. citric acid) as an auxiliary stabilizer or a sugar sulfate (e.g. a heparin) and an isotonizing agent, a preservative germicide, a chelating agent, a viscous agent, etc., and regulating the pH to 7-10. The pharmaceutical preparation is useful for a treating thrombogenic tendency caused by congenital AT-III deficiency and disseminated intravascular coagulation syndrome accompanied by a reduction in the AT-III.  The daily dose thereof is 1,000-3,000 units (or 20-60 units/kg) and further 40-60 units/kg at a time when used as an emergency treatment such as obstetric or surgical treatment.
Patients admitted to the intensive care unit (ICU) usually require use of hypnotics and sedatives to ensure comfort and proper adaptation to mechanical ventilation. An important requirement for an adequate sedation is frequent and proper assessment of its depth. Inadequate sedation can lead to problems of over-sedation, under-sedation and/or delirium in ICU, especially in elderly patients. The main objective od the study is To compare the total dose of sedative use and the rate of over-sedation in patients over 65 years admitted to the ICU, adjusting sedation by monitoring with BIS® versus monitoring with the exclusive use of sedation scales. METHODS. A randomized, clinical trial including patients over 65 years who were admitted to the ICU affected with medical or surgical pathology of non neurological etiology who required sedation for more than 24 hours to maintain adaptation to mechanical ventilation. Patients were randomized into two groups: the intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60 and; the control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2. The study was approved by the institution's Research Ethics Committee.
NEW MATERIAL:A human tissue factor-activating substance which can activate the VII factor in the coexistence of phospholipids and calcium ion to manifest a blood coagulation activity with the optimal pH of 7.5-8.5, capable of manifesting the activity in a pH range of 5.5-12, having a molecular weight of 54,000-60,000 and detectable in human urine. USE:A hemostatic agent for wounds and those of postsurgery, and a therapeutic agent for bleeders having VIII factor-neutralizing antibodies. PREPARATION:For example, human tissue factor(TF) apoprotein isolated from human placenta and purified by a conventional method is decomposed with CNBr and a fragment of the apoprotein on the amino group terminal side thereof is collected. The fragment is employed in an antigen to prepare a monoclonal antibody. The antibody is combined with an insoluble carrier and brought into contact with human urine to adsorb the TF in the human urine. The adsorbed TF is eluted with a 3MNaSCN solution, etc., to provide the human tissue factor-activating substance.
PURPOSE: To investigate the effects of different cortical bone thickness and jaw bone density at implant sites on intraoperative pain during implant surgery.
METHODS: One hundred and eighty-seven patients(263 implant sites) who underwent implant placement surgery at the Fourth Affiliated Hospital of Nanchang University from August 2021 to August 2022 were selected to investigate the effects of different cortical bone thickness and jaw bone density HU values at implant sites on the anesthetic effect under local infiltration anesthesia with epinephrine in articaine. SPSS 26.0 software package was used for data analysis.
RESULTS: The mean cortical bone thickness at the painful sites[(3.90±1.36) mm] was significantly greater than that at the non-painful sites [(2.24±0.66) mm], and the difference was statistically significant(P<0.05). The differences in cortical bone thickness in the mandibular anterior, premolar, and molar regions were statistically significant in the comparison of pain and non-pain sites. The mean HU value of bone density was (764.46±239.75) for the painful sites and (612.23±235.31) for the non-painful sites, with significant difference(P<0.05). The difference was not significant(P>0.05) when comparing the HU values of painful sites with non-painful sites in the mandibular anterior teeth and anterior molar region, while the difference was significant(P<0.05) when comparing the HU values of painful sites with non-painful sites in the mandibular molar region.
CONCLUSIONS: Sites with large cortical bone thickness have a greater effect on blocking infiltrative anesthetic penetration and are more prone to intraoperative pain during implantation. In the mandibular anterior and premolar regions, the HU value of the implant sites had less effect on infiltrative anesthetic penetration, and the effect was greater in the mandibular molar region, and the implant sites with high HU values in the mandibular molar region were more likely to have intraoperative pain. When the cortical bone thickness in the planned implant site is greater than 3.9 mm and the mean bone density in the mandibular molar region is greater than 665 HU. If there is sufficient safe distance for hole operation, it is recommended to apply mandibular nerve block anesthesia combined with articaine infiltration anesthesia to avoid intraoperative pain and bad surgical experience for the patients.